Safety, pharmacokinetics and target engagement of novel <scp>RIPK1</scp> inhibitor <scp>SAR443060</scp> ( <scp>DNL747</scp> ) for neurodegenerative disorders: Randomized, <scp>placebo‐controlled</scp> , <scp>double‐blind</scp> phase I/Ib studies in healthy subjects and patients-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 ( DNL747 ) for neurodegenerative disorders: Randomized, placebo‐controlled , double‐blind phase I/Ib studies in healthy subjects and patients

Published:2022-06 Issue:8 Volume:15 Page:2010-2023
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Vissers Maurits F. J. M.¹²^ORCID,Heuberger Jules A. A. C.¹^ORCID,Groeneveld Geert Jan¹²^ORCID,Oude Nijhuis Jerome³,De Deyn Peter Paul³⁴,Hadi Salah⁵,Harris Jeffrey⁶,Tsai Richard M.⁶,Cruz‐Herranz Andres⁶,Huang Fen⁶,Tong Vincent⁶,Erickson Rebecca⁶,Zhu Yuda⁶,Scearce‐Levie Kimberly⁶,Hsiao‐Nakamoto Jennifer⁶,Tang Xinyan⁶,Chang Megan⁶,Fox Brian M.⁶,Estrada Anthony A.⁶,Pomponio Robert J.⁷,Alonso‐Alonso Miguel⁷,Zilberstein Moshe⁷,Atassi Nazem⁷,Troyer Matthew D.⁶,Ho Carole⁶

Affiliation:

1. Centre for Human Drug Research Leiden The Netherlands

2. Leiden University Medical Center Leiden The Netherlands

3. Department of Neurology and Alzheimer Center, University of Groningen University Medical Center Groningen Groningen The Netherlands

4. Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born‐Bunge University of Antwerp Antwerp Belgium

5. PRA Health Sciences Groningen The Netherlands

6. Denali Therapeutics Inc. South San Francisco California USA

7. Sanofi Genzyme Cambridge Massachusetts USA

Funder

Sanofi Genzyme

Denali Therapeutics

Publisher